MedDataX Logo

Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)

NCT ID: NCT00266357

Last Updated: 2015-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)

NCT00266344

Primary Insomnia
COMPLETED PHASE2

Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)

NCT00094666

Primary Insomnia
TERMINATED PHASE3

Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)

NCT00094627

Primary Insomnia
COMPLETED PHASE3

An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)

NCT00103818

Insomnia
COMPLETED PHASE3

An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)

NCT00102154

Insomnia
WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Insomnia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)

Intervention Type DRUG

Placebo / Duration of Treatment: 2 days for screening period

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a diagnosis of primary insomnia

Exclusion Criteria

* Patients with an active psychiatric disorder other than primary insomnia
Minimum Eligible Age

20 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

H. Lundbeck A/S

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2005_107

Identifier Type: -

Identifier Source: secondary_id

0928-041

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)
NCT00102167 COMPLETED PHASE3
Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)
NCT00095069 COMPLETED PHASE3
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
NCT00420810 TERMINATED PHASE3
Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)
NCT00095043 COMPLETED PHASE3
Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
NCT01021852 COMPLETED PHASE2
A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia
NCT00209937 COMPLETED PHASE3
A Study of Gaboxadol in Primary Insomnia
NCT00209963 COMPLETED PHASE3
A Study of Gaboxadol in Primary Insomnia
NCT00209846 COMPLETED PHASE3
Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia
NCT00280423 COMPLETED PHASE2
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
NCT00784875 COMPLETED PHASE2
A Study of Gaboxadol in Primary Insomnia
NCT00209924 COMPLETED PHASE3
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
NCT00280436 COMPLETED PHASE2
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
NCT00792298 COMPLETED PHASE2
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)
NCT01097629 COMPLETED PHASE3
An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia
NCT03338764 WITHDRAWN PHASE3
A Study of LY2624803 in Participants With Transient Insomnia
NCT01779830 COMPLETED PHASE1
A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep
NCT00655369 COMPLETED PHASE2
Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder
NCT06279286 NOT_YET_RECRUITING PHASE1/PHASE2
A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia
NCT00209950 COMPLETED PHASE3
To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
NCT00426816 COMPLETED PHASE2
A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)
NCT00506389 COMPLETED PHASE3
A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia
NCT00569972 COMPLETED PHASE2
A Study of LY2624803 in Japanese Participants With Transient Insomnia
NCT01784614 COMPLETED PHASE1
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)
NCT01097616 COMPLETED PHASE3
Treatments for Insomnia in Patients With Parkinson's Disease
NCT01489982 COMPLETED EARLY_PHASE1